LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma

NCT01820364 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

15

Enrollment

INDUSTRY

Sponsor class

Stopped Study was withdrawn due to scientific and business considerations.

Conditions

Melanoma

Interventions

DRUG: LGX818

Sponsor

Array BioPharma